- -

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes

Mostrar el registro sencillo del ítem

Ficheros en el ítem

[Cerrado]
Nombre: Rossetti - Differ ...
Tamaño: 626.7Kb
Formato: PDF
Descripción: Versión editorial
Solicitar una copia al autor
dc.contributor.author Porcellati, Francesca es_ES
dc.contributor.author Lucidi, Paola es_ES
dc.contributor.author Rossetti, Paolo es_ES
dc.contributor.author Candeloro, Paola es_ES
dc.contributor.author Andreoli, Anna Marinelli es_ES
dc.contributor.author Marzotti, Stefania es_ES
dc.contributor.author Cioli, Patrizia es_ES
dc.contributor.author Bolli, Geremia B. es_ES
dc.contributor.author Fanelli, Carmine G. es_ES
dc.date.accessioned 2013-11-25T13:50:15Z
dc.date.issued 2011
dc.identifier.issn 0149-5992
dc.identifier.uri http://hdl.handle.net/10251/33976
dc.description.abstract [EN] OBJECTIVE-To assess the role of adiposity on the pharmacodynamics of basal insulins NPH, detemir, and glargine in type 2 diabetes mellitus (T2DM), as estimated by glucose infusion rate (GIR) and endogenous glucose production (EGP) rate in the euglycemic clamp. RESEARCH DESIGN AND METHODS-We examined the variables that best predicted GIR and EGP in 32-h clamp studies after treatment with subcutaneous injection of 0.4 units/kg NPH, detemir, and glargine in 18 T2DM subjects (crossover). RESULTS-A multiple regression analysis revealed that BMI best predicted GIR variation during the clamp. BMI was inversely correlated with GIR in all three insulin treatments, but was statistically significant in detemir treatment only. BMI correlated positively with residual suppression of EGP in detemir, but not with glargine and NPH treatments. CONCLUSIONS-Adiposity blunts the pharmacodynamics of all basal insulins in T2DM. However, as adiposity increases, the effect of detemir is lower versus NPH and glargine. es_ES
dc.description.sponsorship F.P., P.L., P.R., and C.G.F. received grants from various companies (sanofi-aventis, Eli Lilly, Bristol-Myers Squibb, Novartis, and Merck Sharp & Dohme) for participating at meetings and congresses. G.B.B. received honoraria for scientific advising and consulting from the following companies: sanofi-aventis, MannKind, and Eli Lilly. No other potential conflicts of interest relevant to this article were reported.
dc.language Inglés es_ES
dc.publisher American Diabetes Association es_ES
dc.relation.ispartof Diabetes Care es_ES
dc.rights Reserva de todos los derechos es_ES
dc.title Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes es_ES
dc.type Artículo es_ES
dc.embargo.lift 10000-01-01
dc.embargo.terms forever es_ES
dc.identifier.doi 10.2337/dc11-1064
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Instituto Universitario de Automática e Informática Industrial - Institut Universitari d'Automàtica i Informàtica Industrial es_ES
dc.description.bibliographicCitation Porcellati, F.; Lucidi, P.; Rossetti, P.; Candeloro, P.; Andreoli, AM.; Marzotti, S.; Cioli, P.... (2011). Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes. Diabetes Care. 34(12):2521-2523. doi:10.2337/dc11-1064 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion http://dx.doi.org/10.2337/dc11-1064 es_ES
dc.description.upvformatpinicio 2521 es_ES
dc.description.upvformatpfin 2523 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 34 es_ES
dc.description.issue 12 es_ES
dc.relation.senia 220375
dc.identifier.pmid 21972412
dc.identifier.pmcid PMC3220859
dc.contributor.funder Bristol-Myers Squibb es_ES
dc.contributor.funder Novartis Foundation es_ES
dc.contributor.funder Eli Lilly and Company es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem